Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Selective inhibition of GSK3α corrects diverse impairments in the Fmr1−/ymouse model of fragile X syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Dudek, S. M., & Bear, M. F. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4363 · Cited by 1,708 · cited 1×
“Homosynaptic NMDAR-dependent LTD was induced by delivering low-frequency stimulation (LFS; 900 pulses at 3 Hz) at the same stimulation intensity as baseline (104).”
MethodSelf-citationThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Self-citationCellular and network mechanisms of rhythmic recurrent activity in neocortex
Sanchez-Vives, M. V., & McCormick, D. A. (2000) · Nature Neuroscience · doi:10.1038/79848 · Cited by 1,539 · cited 2×
“UP states are generated by recurrent synaptic circuitry and resemble neurophysiological rhythms measured in vivo, such as during slow-wave sleep (55, 56).”
BackgroundMethodMolecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
Naisbitt, S., Kim, E., Tu, J. C., Xiao, B., Sala, C., Valtschanoff, J., Weinberg, R. J., Worley, P. F., & Sheng, M. (1999) · Neuron · doi:10.1016/s0896-6273(00)80809-0 · Cited by 1,009
Correction of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979 · cited 6×
“The phenotype of elevated bulk protein synthesis in acutely prepared hippocampal slices has been widely reproduced in multiple laboratories and animal models of FXS (50, 51, 77, 92) and is consistent with observations in Fmr1−/y mice in vivo (23, 52, 93), as well as in cultured neurons from Fmr1−/y mice and patient-de…”
BackgroundMethodResultInfluentialSelf-citationAdvances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596
Gibson, J. R., Bartley, A. F., Hays, S. A., & Huber, K. M. (2008) · Journal of Neurophysiology · doi:10.1152/jn.90752.2008 · Cited by 529 · cited 1×
“Slices were then transferred to an aCSF that mimics physiological ionic concentrations in vivo (56, 103), containing 126 mM NaCl, 5 mM KCl, 1.”
MethodSelf-citationSuppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521
Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Self-citationRapid Neocortical Dynamics: Cellular and Network Mechanisms
Haider, B., & McCormick, D. A. (2009) · Neuron · doi:10.1016/j.neuron.2009.04.008 · Cited by 441
Osterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3888-10.2010 · Cited by 384 · cited 10×
“The data showed comparable ERK1/2 phosphorylation after mGluR5 activation in vehicle and BRD0705-treated slices and, in agreement with previous findings (51), no difference between wild-type and Fmr1−/y mice.”
BackgroundMethodResultInfluentialSelf-citationThe Pathophysiology of Fragile X (and What It Teaches Us about Synapses)
Bhakar, A. L., Dölen, G., & Bear, M. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153138 · Cited by 370 · cited 4×
“Because FMRP functions normally as a translational repressor (95), it has been proposed that increased constitutive protein synthesis may be a proximal cause of other diverse FXS phenotypes (6, 96).”
BackgroundInfluentialSelf-citationPorter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089839 · Cited by 308
Dysregulation and restoration of translational homeostasis in fragile X syndrome
Richter, J. D., Bassell, G. J., & Klann, E. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4001 · Cited by 275 · cited 3×
“Studies in animal models of FXS (flies, fish, mice, and rats) have shown that disease modification is possible, even after the onset of symptoms (6, 8).”
BackgroundMethodBerry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4109 · Cited by 270
Qin, M., Kang, J., Burlin, T. V., Jiang, C., & Smith, C. B. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0093-05.2005 · Cited by 263
Toward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome
Krueger, D. D., & Bear, M. F. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061109-134644 · Cited by 259 · cited 2×
“FXS has offered one of the first opportunities to fulfill the promise of molecular medicine in a complex neuropsychiatric disease: progressing from gene identification to studies of pathophysiology in genetically validated animal models to therapeutic target identification and, ultimately, to clinical trials (9).”
BackgroundSelf-citationDisrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome
Ronesi, J. A., Collins, K. A., Hays, S. A., Tsai, N.-P., Guo, W., Birnbaum, S. G., Hu, J.-H., Worley, P. F., Gibson, J. R., & Huber, K. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3033 · Cited by 251
Self-citationOsterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230 · cited 4×
“BRD0705 corrects cortical hyperexcitability Increased excitability in the cerebral cortex is another robust and reproducible FXS phenotype that can be corrected by inhibition of mGluR5 or downstream signaling pathways coupled to translation (49, 53, 54).”
BackgroundResultInfluentialSelf-citationOpen-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome
Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Weiler, I. J., & Greenough, W. T. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31817dc447 · Cited by 215 · cited 1×
“Although results in an open-label trial were suggestive of benefit in FXS (28), numerous side effects limit the potential of lithium as a therapeutic in children and adolescents with FXS and other autism spectrum disorders (29).”
ResultMin, W. W., Yuskaitis, C. J., Yan, Q., Sikorski, C., Chen, S., Jope, R. S., & Bauchwitz, R. P. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.09.017 · Cited by 146
Till, S. M., Asiminas, A., Jackson, A. D., Katsanevaki, D., Barnes, S. A., Osterweil, E. K., Bear, M. F., Chattarji, S., Wood, E. R., Wyllie, D. J. A., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv299 · Cited by 109 · cited 1×
“A consistent observation in hippocampal slices from the Fmr1−/y mouse and rat models of FXS is elevated basal protein synthesis and altered protein synthesis– dependent synaptic plasticity compared to wild-type animals (6, 7).”
Self-citationMetabotropic glutamate receptor 5 as drug target for Fragile X syndrome
Scharf, S. H., Jaeschke, G., Wettstein, J. G., & Lindemann, L. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.004 · Cited by 106
Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant
Pop, A. S., Levenga, J., de Esch, C. E. F., Buijsen, R. A. M., Nieuwenhuizen, I. M., Li, T., Isaacs, A., Gasparini, F., Oostra, B. A., & Willemsen, R. (2014) · Psychopharmacology · doi:10.1007/s00213-012-2947-y · Cited by 93
Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study
Huang, R.-Y., Hsieh, K.-P., Huang, W.-W., & Yang, Y.-H. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.181362 · Cited by 83
Asiminas, A., Jackson, A. D., Louros, S. R., Till, S. M., Spano, T., Dando, O., Bear, M. F., Chattarji, S., Hardingham, G. E., Osterweil, E. K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0498 · Cited by 78 · cited 5×
“In support of this theory, it has been shown repeatedly that inhibitors of mGluR5, Ras, or MEK (mitogenactivated protein kinase kinase), the upstream regulator of ERK, all correct excessive protein synthesis and improve electrophysiological and behavioral phenotypes in Fmr1−/y mice (48–51, 73–77).”
BackgroundInfluentialSelf-citationQin, M., Huang, T., Kader, M., Krych, L., Xia, Z., Burlin, T., Zeidler, Z., Zhao, T., & Smith, C. B. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv034 · Cited by 62
Choi, C. H., Schoenfeld, B. P., Bell, A. J., Hinchey, J., Rosenfelt, C., Gertner, M. J., Campbell, S. R., Emerson, D., Hinchey, P., Kollaros, M., et al. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00136 · Cited by 46 · cited 3×
“Serine-21 of GSK3, hypophosphorylated in Fmr1−/y mice (19, 20, 83), is a substrate of the protein kinases Akt and protein kinase A (PKA) (89).”
Backgroundde Esch, C. E. F., van den Berg, W. E., Buijsen, R. A. M., Jaafar, I. A., Nieuwenhuizen-Bakker, I. M., Gasparini, F., Kushner, S. A., & Willemsen, R. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.12.021 · Cited by 45
Cited by
Wang, L., Li, J., & Di, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21867 · Cited by 261
Recent advances in gene therapy for neurodevelopmental disorders with epilepsy
Turner, T. J., Zourray, C., Schorge, S., & Lignani, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15168 · Cited by 71
Hyperexcitability and homeostasis in fragile X Syndrome.
Liu, X., Kumar, V., Tsai, N.-P., & Auerbach, B. D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.805929 · Cited by 53
D’Incal, C., Broos, J., Torfs, T., Kooy, R. F., & Vanden Berghe, W. (2022) · Cells · doi:10.3390/cells11081325 · Cited by 29
Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors
Amaral, B., Capacci, A., Anderson, T., Tezer, C., Bajrami, B., Lulla, M., Lucas, B., Chodaparambil, J. V., Marcotte, D., Kumar, P. R., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00476 · Cited by 22
Metadata
- Authors
- McCamphill, P. K., Stoppel, L. J., Senter, R. K., Lewis, M. C., Heynen, A. J., Stoppel, D. C., Sridhar, V., Collins, K. A., Shi, X., Pan, J. Q., Madison, J., Cottrell, J. R., Huber, K. M., Scolnick, E. M., Holson, E. B., Wagner, F. F., & Bear, M. F.
- Venue
- Science Translational Medicine
- Published
- 2020-05-20
- Volume
- 12
- Issue
- 544
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3028560525
- Cited by
- 59
- References
- 32
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.